Medicare Spending Implications for Semaglutide Under Voluntary Price Agreements

JAMA 2026 Open access

Read full text
Authors: Stacie B. Dusetzina, Grace Castle, Jihye Han, Ashley A. Leech, Jinyi Zhu
DOI: 10.1001/jama.2026.2615
Cited by: 3
References: 6

Abstract

This study compares expected total Medicare spending on semaglutide in 2027 under voluntary price agreement participation vs nonparticipation and estimates beneficiaries eligible for expanded obesity-indication coverage whose treatment costs could be offset with savings from the agreement.

Fields of Study & Subjects

Medication Adherence and Compliance Diabetes Treatment and Management Health Systems Economic Evaluations Quality of Life

Publication details

Journal / source
JAMA
Publisher
American Medical Association (AMA)
Volume
335
Issue
16
Pages
1442–1442
Publication date
2 April 2026
Language
EN